SCHEMBL2902480

SCHEMBL2902480

[CH]=Cc1cc2ccccc2s1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 0.67
GSK3B P49841 1/20 0.47
TUBB4A P04350 2/20 0.46
TUBB P07437 2/20 0.46
TUBA3C P0DPH7 2/20 0.46
TUBA1B P68363 2/20 0.46
TUBA4A P68366 2/20 0.46
TUBB4B P68371 2/20 0.46
TUBB3 Q13509 2/20 0.46
TUBB2A Q13885 2/20 0.46
TUBB8 Q3ZCM7 2/20 0.46
TUBA3E Q6PEY2 2/20 0.46
TUBA1A Q71U36 2/20 0.46
TUBA1C Q9BQE3 2/20 0.46
TUBB6 Q9BUF5 2/20 0.46
TUBB2B Q9BVA1 2/20 0.46
TUBB1 Q9H4B7 2/20 0.46
ASIC3 Q9UHC3 1/20 0.45
LOXL2 Q9Y4K0 1/20 0.45
MGLL Q99685 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27644653 0.80 CYP2A6 (0.64) CYP2A6GSK3BTUBB4ATUBBTUBA3C
SCHEMBL56884 0.80 CYP2A6 (1.00) CYP2A6GSK3BTUBB4ATUBBTUBA3C
SCHEMBL27556684 0.80 CYP2A6 (0.64) CYP2A6GSK3BTUBB4ATUBBTUBA3C
SCHEMBL29629031 0.80 CYP2A6 (1.00) CYP2A6GSK3BTUBB4ATUBBTUBA3C
SCHEMBL1567214 0.80 CYP2A6 (0.64) CYP2A6GSK3BTUBB4ATUBBTUBA3C
SCHEMBL7416778 0.80 CYP2A6 (0.64) CYP2A6GSK3BTUBB4ATUBBTUBA3C
SCHEMBL8996544 0.80 CYP2A6 (0.64) CYP2A6GSK3BTUBB4ATUBBTUBA3C
SCHEMBL7079637 0.80 CYP2A6 (0.64) CYP2A6GSK3BTUBB4ATUBBTUBA3C
SCHEMBL1567141 0.80 CYP2A6 (0.64) CYP2A6GSK3BTUBB4ATUBBTUBA3C
SCHEMBL12884253 0.80 CYP2A6 (0.64) CYP2A6GSK3BTUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105408325-A Cyanotriazole compounds OTSUKA PHARMA CO LTD 2016-03-16 CN claimed
CN-105408325-B cyanotriazole compounds 大塚制药株式会社 2019-10-22 CN disclosed
EP-2759543-B1 CHROMENE COMPOUND AND CURABLE COMPOSITION TOKUYAMA CORP (JP) 2017-07-19 EP disclosed
US-9487693-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2016-11-08 US disclosed
EP-2725017-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2016-06-29 EP disclosed
CN-105408325-A Cyanotriazole compounds OTSUKA PHARMA CO LTD 2016-03-16 CN disclosed
EP-2669277-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2015-07-01 EP disclosed
EP-2684886-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2015-06-03 EP disclosed
EP-2669278-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2015-05-27 EP disclosed
US-8916071-B2 Chromene compound and curable composition TOKUYAMA CORPORATION (JP) 2014-12-23 US disclosed
EP-1655293-A2 Chromene compound Tokuyama Corporation (JP) 2006-05-10 EP disclosed
CN-1590357-A Lightfast additive having uv-absorbing moiety and ink composition including the same SAMSUNG ELECTRONICS CO LTD (KR) 2005-03-09 CN disclosed
US-20040237837-A1 Lightfast additive having UV-absorbing moiety and ink composition including the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2004-12-02 US disclosed
US-6723859-B2 BASE STRUCTURE IS A CHROMENE(3,2-A)FLUORENE RING CONTAINING SPIRO-FUSED RINGS; PHOTOCHROMIC LENSES; LARGE FADING RATE, LESS COLOR WHEN DETERIORATED, AND EXCELLENT LIGHT RESISTANCE IN THE PHOTOCHROMIC PROPERTIES TOKUYAMA CORPORATION (JP) 2004-04-20 US disclosed
US-20040014995-A1 Chromene compounds KAWABATA YUICHIRO (JP) 2004-01-22 US disclosed
US-20030096117-A1 Chromene compound TOKUYAMA CORPORATION (JP) 2003-05-22 US disclosed
US-6469076-B1 Chromene compounds TOKUYAMA CORPORATION (JP) 2002-10-22 US disclosed
US-6384065-B1 CONTROL THE FUNCTIONS OF PROTEINS SUCH AS ENZYMES AND RECEPTOR FORTREATING INFLAMMATORY DISEASES SUCH AS RHEUMATOID ARTHRITIS, TOYAMA CHEMICAL CO., LTD. (JP) 2002-05-07 US disclosed
EP-1184379-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2002-03-06 EP disclosed
EP-1116723-A1 CHROMENE COMPOUNDS TOKUYAMA CORPORATION (JP) 2001-07-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040237837-A1 Lightfast additive having UV-absorbing moiety and ink composition including the same CDK4, CDKL4, UGT1A4 CYP2A6 1337/4885GSK3B 4140/4885TUBB4A 737/4885
US-20040014995-A1 Chromene compounds SMARCE1, SMARCB1, SMARCA2 CYP2A6 2241/4885GSK3B 2854/4885TUBB4A 3251/4885
US-20030096117-A1 Chromene compound SMARCE1, SMARCD2, SMARCB1 CYP2A6 2342/4885GSK3B 2866/4885TUBB4A 3494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.